Latest news with #SBCMedical
Associated Press
8 hours ago
- Business
- Associated Press
SBC Medical added to membership of Russell 3000® Index
IRVINE, Calif.--(BUSINESS WIRE)--Jun 27, 2025-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at View source version on CONTACT: SBC Medical Group Holdings Incorporated (Asia) Hikaru Fukui / Head of Investor Relations E-mail:[email protected] LLC (In the US) Bill Zima / Managing Partner Email:[email protected] KEYWORD: SOUTHEAST ASIA SINGAPORE NORTH AMERICA ASIA PACIFIC JAPAN EUROPE UNITED STATES UNITED KINGDOM CALIFORNIA INDUSTRY KEYWORD: MEDICAL SUPPLIES TECHNOLOGY PROFESSIONAL SERVICES OTHER HEALTH HEALTH HEALTH TECHNOLOGY MEDICAL DEVICES COSMETICS RETAIL DATA ANALYTICS SOFTWARE SOURCE: SBC Medical Group Holdings Incorporated Copyright Business Wire 2025. PUB: 06/27/2025 07:30 PM/DISC: 06/27/2025 07:31 PM
National Post
8 hours ago
- Business
- National Post
SBC Medical added to membership of Russell 3000® Index
Article content IRVINE, Calif. — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Article content Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Article content Article content Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' Article content For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. Article content About SBC Medical Article content SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. Article content For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. Article content FTSE Russell is wholly owned by London Stock Exchange Group. Article content Forward-Looking Statements Article content This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at Article content Article content Article content
Yahoo
8 hours ago
- Business
- Yahoo
SBC Medical added to membership of Russell 3000® Index
IRVINE, Calif., June 27, 2025--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical"), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments:"The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark." For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at View source version on Contacts SBC Medical Group Holdings Incorporated (Asia)Hikaru Fukui / Head of Investor Relations E-mail: ir@ ICR LLC (In the US)Bill Zima / Managing Partner Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
8 hours ago
- Business
- Business Wire
SBC Medical added to membership of Russell 3000 ® Index
IRVINE, Calif.--(BUSINESS WIRE)-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Fiona Bassett, CEO of FTSE Russell, An LSEG Business, comments: 'The Russell indexes have continuously adapted to the evolving dynamic US economy, and it's crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.' For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at
Globe and Mail
18-06-2025
- Business
- Globe and Mail
Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.' Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field. Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration. Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice. The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 Official website： Presentation Topics Chair / Speaker Job Title Title Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing 【Special Lecture/Chair】The future of cosmetic medicine and AI Daisuke Nakamura Chief Medical Director of Shonan Beauty Group, Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation Kazuhiro Igawa Representative Assistant and Technical Advisor, Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management 【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution 【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF 【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector? 【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins 【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~ 【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler Poster Presentations Speaker Job Title Title Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction. Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~ Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid Kaito Kuzushima Ginza Clinic Director Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】 Aiko Ssasaki Kawagoe Area Area Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty. Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit Contacts In Asia: SBC Medical Group Holdings Incorporated Hikaru Fukui / Head of Investor Relations E-mail: ir@ In the US: ICR LLC Bill Zima / Managing Partner Email:
